4 news items
Dynavax to Present at Upcoming Investor Conferences
DVAX
28 May 24
(NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative
Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.
DVAX
14 May 24
is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases
Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates
DVAX
8 May 24
innovative vaccines, today reported financial results and provided a business update for the quarter ended
Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
DVAX
24 Apr 24
biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2024 financial results
- Prev
- 1
- Next